NCT02132169

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 512 (actual)
• Sponsor: Aciex Therapeutics, Inc. · Industry
• Sex: All
• Age: 2 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of AC-170 0.24% used twice daily in Healthy Adult Subjects and in Pediatric subjects with a history or family history of atopic disease (including allergic conjunctivitis).

Conditions

• Atopic Disease (Including Allergic Conjunctivitis)

Interventions

Type	Name	Description
DRUG	Drug: AC-170 0.24%
DRUG	AC-170 0%

Timeline

• Start date: 2014-05-01
• Primary completion: 2014-10-01
• Completion: 2014-10-01
• First posted: 2014-05-07
• Last updated: 2017-09-11
• Results posted: 2017-07-26

Locations

1 site across 1 country: United States